BNT162b2 vaccine effectiveness 92 percent for teens ages 12 to 17

(HealthDay)—For adolescents ages 12 to 17 years, the effectiveness of full vaccination with two doses of the Pfizer-BioNTech vaccine is 92 percent against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), according to research published in the Dec. 31 issue of the U.S. Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report.

source https://medicalxpress.com/news/2021-12-bnt162b2-vaccine-effectiveness-percent-teens.html